Clinical Trial Update: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating zoledronic acid to maintain bone mass after stopping denosumab in postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Denosumab (denosumab)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: 424 General Military Hospital | Conditions: Postmenopausal Osteoporosis | Phase 4 | Status: COMPLETED